Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02121990 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Paclitaxel,
DRUG: Bevacizumab
DRUG: Cisplatin
DRUG: Olaparib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]